You've probably heard this before: Pharmaceutical stocks can bring an element of safety to your portfolio. Why is this the case? These companies make drugs doctors and patients rely on -- and that means no matter what the economy is doing, doctors will continue prescribing and patients will continue buying these treatments. All of this equals a rather steady stream of revenue for a pharma company, and this could translate into positive stock price performance over time.Sales of these drugs also have helped ...

Investors seeking a steadily growing passive income stream want to turn their heads toward the healthcare sector. Unlike with enterprise software sales or consumer goods, spending on healthcare tends to move in a positive direction regardless of what's happening to the overall economy.In 2023, the national health expenditure grew 7.5% to $4.9 trillion. With strong positions in the pharmaceutical and medical technology industries, AbbVie (ABBV -1.23%), Johnson & Johnson (JNJ -0.50%), and Medtronic (MDT 1.06% ...

Introduction If there's one thing we have been talking about almost nonstop, it's inflation. As you can imagine, this article won't be an exception. In general, inflation is an important topic, as it's a silent killer of our wealth. While ...

AbbVie (ABBV) closed the latest trading day at $173.70, indicating a +1.37% change from the previous session's end. This change outpaced the S&P 500's 0.21% loss on the day. Elsewhere, the Dow saw a downswing of 0.16%, while the tech-heavy Nasdaq depreciated by 0.89%.The drugmaker's shares have seen a decrease of 0.97% over the last month, surpassing the Medical sector's loss of 2.46% and the S&P 500's loss of 1.56%.The upcoming earnings release of AbbVie will be of great interest to investors. The company' ...

Key Points Company and Industry 1. **Company**: AbbVie Inc. (NYSE: ABBV) 2. **Event**: J.P. Morgan 43rd Annual Healthcare Conference 3. **Date**: January 15, 2025 4. **Time**: 11:15 AM ET 5. **Participants**: - Rob Michael - CEO - Scott Reents - Executive Vice President, CFO - Jeff Stewart - Executive Vice President, Chief Commercial Officer - Roopal Thakkar - Executive Vice President, Research & Development, Chief Scientific Officer - Chris Schott - J.P. Morgan [1] Core Views and Arguments 1. **CEO Rob Michael's Performance**: Rob Michael expresses satisfaction with the company's performance, noting that they are beating their top line by $1.8 billion and earnings are well ahead of expectations. 2. **Focus on Growth Platform**: Michael emphasizes the importance of executing the growth platform effectively, which he believes will provide a clear runway for growth for at least the next 8 years. 3. **Pipeline Expansion**: Michael also highlights the need to add to the pipeline to ensure sustained growth beyond the current period. [3][4] Other Important Points 1. **Investor Perception**: Michael acknowledges that investors may not fully appreciate the company's clear runway for growth over the next 8 years. 2. **Management Team**: The conference call features a broad swath of AbbVie's management team, indicating a collaborative approach to the company's strategy and execution. [3][4]

AbbVie’s (ABBV) stock has declined 8% in the past three months. A lot of this price decline is due to the poor performance of the overall drug and biotech sector in the past couple of months after Trump picked Robert F. Kennedy Jr., a vaccine skeptic, to be the next secretary of the Department of Health and Human Services, the agency that oversees the FDA.This, coupled with disappointing third-quarter sales and profits, guidance cuts and pipeline setbacks took a toll on the overall drug and biotech industry ...

Dividend growth investing is a powerful strategy for building lasting wealth. Companies that consistently raise their dividends tend to possess durable competitive advantages, robust cash flows, and shareholder-friendly management teams.These characteristics make dividend growth stocks compelling investments in any market environment. The strategy's success stems from the financial discipline and steady execution these companies demonstrate, making them ideal portfolio cornerstones for investors seeking bot ...

If you're a retiree looking for dependable and reliable dividend income, there are many quality stocks out there that can be suitable options for your portfolio. The stocks I've listed below pay above-average yields, grow their dividends on a regular basis, and aren't volatile investments. These can be the types of stocks that you can buy and forget about.Coca-Cola (KO 0.95%), Procter & Gamble (PG 0.18%), and AbbVie (ABBV 0.90%) can give some good diversification for your portfolio while also providing exce ...

Retirement Planning and Investment Strategy - The Retirement Forum offers actionable ideas, a high-yield safe retirement portfolio, and macroeconomic outlooks to help maximize capital and income [1] - The Value Portfolio specializes in building retirement portfolios using a fact-based research strategy, including extensive readings of 10Ks, analyst commentary, market reports, and investor presentations [2] AbbVie Overview - AbbVie (NYSE: ABBV) is one of the largest pharmaceutical companies globally with a market cap exceeding $300 billion [2] - The company's success is attributed to its spin-off from Abbott Laboratories (ABT) [2]

Methodology and Company Selection - The article outlines a methodology for selecting pharmaceutical companies, particularly those focused on developing cancer treatments [1] - Five specific pharmaceutical companies are highlighted as promising investment opportunities due to their focus on cancer medication development [1] Allka Research Overview - Allka Research has over two decades of experience in investment, specializing in ETFs, commodities, technology, and pharmaceutical companies [1] - The company is known for its conservative approach, consistently identifying undervalued assets [1] - Allka Research aims to simplify investment strategies, making them accessible to both seasoned and novice investors [1] - The company shares its expertise through Seeking Alpha, contributing thought-provoking analyses and informed perspectives [1] Disclosure and Independence - The analyst has no stock, option, or derivative positions in the mentioned companies and no plans to initiate any within the next 72 hours [2] - The article represents the analyst's own opinions and is not influenced by any compensation or business relationships with the mentioned companies [2]